Literature DB >> 27721850

Risk Factor Clustering in Korean Hypertensive Patients.

Jang Young Kim1.   

Abstract

Entities:  

Year:  2016        PMID: 27721850      PMCID: PMC5054171          DOI: 10.4070/kcj.2016.46.5.613

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


× No keyword cloud information.
Refer to the page 672-680 Hypertension infrequently occurs in isolation from other cardiovascular (CV) risk factors; the Framingham heart study showed that hypertension occurs in isolation less than 10%.1) It tends to cluster with other atherogenic risk factors (including dyslipidemia, abdominal obesity and diabetes) that accelerate the clinical CV events. Clustering with two or more major risk factors with hypertension occurs more than 50% in the Framingham heart study.1) Hence, it is important to manage common comorbidities in order to effectively care for hypertension. Therefore, the most national treatment guidelines of hypertension, including Korean guidelines, recommends treating hypertensive patients based on considerations of their comorbid risk factors.2)3) Given the high prevalence of comorbidities and their potential consequences in hypertensive patients, there is substantial interest in the actual prevalence and common comorbidities of Korean hypertensive patients. Noh et al.4) reported on this issue regarding the prevalence of comorbidities among people with hypertension (n=58423) using data from the Korean National Health and Nutrition Examination Survey from 2007-2013. The authors clearly demonstrated that major chronic conditions (including obesity, diabetes mellitus, dyslipidemia, cardiovascular disease, and chronic kidney disease) were more prevalent in adults with hypertension than in those without hypertension. Common comorbidities with hypertension were obesity (60.1%), dyslipidemia (57.6%), and impaired fasting glucose (45.1%). Hypertensive patients with two or more comorbid diseases were 42.2% compared to 17.7% in those of normal blood pressure. In a multivariable adjusted model, the odds ratios (95% confidence interval [CI]) of hypertensive subjects compared to those of normal blood pressure for chronic kidney disease, obesity, dyslipidemia, diabetes mellitus and CVD were 3.94 (1.71-9.07), 2.60 (2.43-2.78), 1.74 (1.62-1.88), 2.22 (95% CI 2.02-2.45), and 2.11 (95% CI 1.78-2.50), respectively. The overall results of this study are in line with previous studies in that the comorbidity proportion of major CV risk factors tended to be highest among hypertensive patients, followed by individuals with prehypertension and normal blood pressure.1)5) In this study common clusters of high blood pressure are associated with metabolic risk factors including obesity, diabetes and dyslipidemia. These current epidemic features are suggestive of a pathophysiological link between obesity-related metabolic derangements and high blood pressure in Koreans. The clustering of risk factors including central obesity, atherogenic dyslipidemia (with low high density lipoprotein-cholesterol, high triglycerides, and small dense low density lipoprotein-cholesterol particles), elevated fasting glucose, vascular inflammation, and elevated blood pressure have been termed as being a metabolic syndrome. Visceral adiposity and insulin resistance appear to play central roles in the risk factor clusters of metabolic syndrome. Subjects with metabolic syndrome also increase the risk of incident CV disease and type 2 diabetes mellitus.6) The prevalence of metabolic syndrome is about one-third of the total Korean population.7) Korea seems to have experienced a rapid increase in the prevalence of a metabolic syndrome during the 2000s, partly due to increasing adoption of Western lifestyle patterns. Some limitations of the Noh et al's study should be considered.4) First, it was cross-sectional, so cause-effect inferences are difficult to establish for the pathophysiologic mechanism between hypertension and its comorbidities. Second, the working definition of major chronic diseases using this study could be different from the exact diagnostic criteria of each disease. It is possible that they could have been misclassified. Finally, laboratory tests were based on a single determination of serum sample, which is subject to random measurement error and may have underestimated the strength of the associations. Despite some limitations, this is the first report to document risk factor clustering in Korean hypertensive patients using data from the Korean National Health and Nutrition Examination Survey. The present study also implicated that optimal CV protection from hypertensive patients requires more than just simply lowering one's blood pressure. There is evidennce that blood pressure control frequently requires the combination of antihypertensive drugs with other therapies, such as aggressive lipid-lowering treatments. In conclusion, the elevated blood pressure itself confers increased risk for CV events in the absence of risk factors, but total CV risk is greater than the sum of its individual risk factors when concomitant elevated blood pressure and the other components of metabolic risk factors are present.8) Therefore, antihypertensive therapy should be tailored to take into account the often associated dyslipidemia, glucose intolerance, obesity and any CV disease condition as well as the character and severity of the individual's high blood pressure.
  8 in total

1.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

2.  Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; P W Wilson; D Levy
Journal:  Arch Intern Med       Date:  1999-10-11

3.  Patterns of multimorbidity in elderly veterans.

Authors:  Michael A Steinman; Sei J Lee; W John Boscardin; Yinghui Miao; Kathy Z Fung; Kelly L Moore; Janice B Schwartz
Journal:  J Am Geriatr Soc       Date:  2012-10-04       Impact factor: 5.562

Review 4.  Metabolic syndrome update.

Authors:  Scott M Grundy
Journal:  Trends Cardiovasc Med       Date:  2015-10-31       Impact factor: 6.677

5.  Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007.

Authors:  Soo Lim; Hayley Shin; Jung Han Song; Soo Heon Kwak; Seon Mee Kang; Ji Won Yoon; Sung Hee Choi; Sung Il Cho; Kyong Soo Park; Hong Kyu Lee; Hak Chul Jang; Kwang Kon Koh
Journal:  Diabetes Care       Date:  2011-04-19       Impact factor: 19.112

Review 6.  2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension.

Authors:  Jinho Shin; Jeong Bae Park; Kwang-Il Kim; Ju Han Kim; Dong Heon Yang; Wook Bum Pyun; Young Gweon Kim; Gheun-Ho Kim; Shung Chull Chae
Journal:  Clin Hypertens       Date:  2015-04-08

7.  Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007-2013.

Authors:  Juhwan Noh; Hyeon Chang Kim; Anna Shin; Hyungseon Yeom; Suk-Yong Jang; Jung Hyun Lee; Changsoo Kim; Il Suh
Journal:  Korean Circ J       Date:  2016-09-28       Impact factor: 3.243

8.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.